A new agreement between the FDA and Avidity Biosciences could further assuage industry concerns about the agency’s stance on ...

Dyne Therapeutics, Inc. announced promising preclinical data for their therapeutic candidate, DYNE-302, which shows potential for functional improvement in facioscapulohumeral muscular dystrophy ...

Provincial Housing Minister Ravi Kahlon says his government has no plans to change its short-term rental (STR) legislation after the BC Real Estate Association called for it to be tweaked for ...

Discover What’s Streaming On: If you couldn’t get enough of the Fear Street movies in 2021, I have good news: There’s a new Fear Street movie, Fear Street: Prom Queen, that began streaming ...

The next season of “Sesame Street” is being brought to you by the big, red letter “N.” Netflix announced a deal Monday with Sesame Workshop, producer of the iconic kids’ show ...

Initially titled 'STR 48', the project is now 'STR 50' with Silambarasan taking on a producer role. The film, directed by Desingh Periyasamy, features music by Yuvan Shankar Raja and ...

Del-brax (AOC 1020) for FSHD showed a 50% reduction in DUX4 gene expression, positioning it as a potential best-in-class therapy. Del-desiran (AOC 1001) for DM1 cleared the FDA's clinical hold ...

Del-brax is the first investigational therapy designed to treat the underlying cause of FSHD, which is caused by the abnormal expression of a gene called double homeobox 4 or DUX4. FSHD is a rare ...

Fulcrum has long believed blocking an enzyme involved in the production of DUX4 with losmapimod — a drug GSK discovered ... to a share sell-off and a flurry of stock downgrades from Wall Street ...

its product candidate for facioscapulohumeral muscular dystrophy (FSHD), that demonstrated robust and durable DUX4 suppression and functional benefit. The data were presented during the 31 st ...